Payment overview · 2025
General Payments
$577.78
29 reported records · 11 companies
Healthcare provider profile · identity verified
Anthony Saweikis, MD
Allopathic & Osteopathic Physicians|Family Medicine · KEYSER, WV · NPI 1407858335
Verified facts
What the public records show
CMS Open Payments records show Anthony Saweikis, MD received $577.78 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Otezla, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 194 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 643 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.62 | 29.9% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $88.77 | 15.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.32 | 15.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.18 | 7.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $38.98 | 6.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.72 | 5.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.39 | 5.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.76 | 4.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.71 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.36 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.97 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $577.78 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $107.36 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $88.77 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $88.77 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.32 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $88.32 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.95 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.81 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $42.18 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $38.98 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $30.72 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.39 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 89 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 194 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 100 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
194 | 27 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
72 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
100 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
643 | 66 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1970 | 231 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1786 | 205 |
| Amlodipine Besylate | Amlodipine Besylate | 1020 | 132 |
| Famotidine | Famotidine | 1001 | 93 |
| Furosemide | Furosemide | 981 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 894 | 143 |
| Lisinopril | Lisinopril | 891 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 848 | 124 |
| Omeprazole | Omeprazole | 822 | 106 |
| Metoprolol Tartrate | Metoprolol Tartrate | 708 | 86 |
| Eliquis | Apixaban | 643 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 621 | 61 |
| Sertraline Hcl | Sertraline Hcl | 615 | 61 |
| Losartan Potassium | Losartan Potassium | 609 | 83 |
| Potassium Chloride | Potassium Chloride | 558 | 56 |
| Trazodone Hcl | Trazodone Hcl | 546 | 45 |
| Metformin Hcl | Metformin Hcl | 532 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 513 | 47 |
| Montelukast Sodium | Montelukast Sodium | 496 | 64 |
| Buspirone Hcl | Buspirone Hcl | 414 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 395 | 77 |
| Donepezil Hcl | Donepezil Hcl | 378 | 32 |
| Carvedilol | Carvedilol | 344 | 37 |
| Gabapentin | Gabapentin | 332 | 52 |
| Simvastatin | Simvastatin | 319 | 35 |
| Finasteride | Finasteride | 317 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 309 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 308 | 38 |
| Tramadol Hcl | Tramadol Hcl | 306 | 64 |
| Allopurinol | Allopurinol | 275 | 29 |
| Ezetimibe | Ezetimibe | 271 | 38 |
| Fluoxetine Hcl | Fluoxetine Hcl | 271 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 269 | 47 |
| Memantine Hcl | Memantine Hcl | 263 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 258 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 237 | 57 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 231 | 30 |
| Spironolactone | Spironolactone | 228 | 23 |
| Xarelto | Rivaroxaban | 219 | 28 |
| Levetiracetam | Levetiracetam | 214 | 17 |
| Prednisone | Prednisone | 214 | 62 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 206 | 12 |
| Mirtazapine | Mirtazapine | 199 | 24 |
| Jardiance | Empagliflozin | 194 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 193 | 23 |
| Baclofen | Baclofen | 184 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 182 | 47 |
| Methotrexate | Methotrexate Sodium | 172 | suppressed |
| Bupropion Xl | Bupropion Hcl | 170 | 31 |
| Januvia | Sitagliptin Phosphate | 159 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 157 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 141 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 34 |
| Lamotrigine | Lamotrigine | 138 | suppressed |
| Olanzapine | Olanzapine | 127 | suppressed |
| Alprazolam | Alprazolam | 120 | 43 |
| Divalproex Sodium | Divalproex Sodium | 119 | suppressed |
| Atenolol | Atenolol | 118 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 118 | 23 |
| Tradjenta | Linagliptin | 117 | suppressed |
| Novolog Flexpen | Insulin Aspart | 116 | 26 |
| Warfarin Sodium | Warfarin Sodium | 116 | 15 |
| Risperidone | Risperidone | 111 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 104 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 103 | suppressed |
| Lorazepam | Lorazepam | 103 | 21 |
| Meloxicam | Meloxicam | 103 | 18 |
| Metformin Hcl Er | Metformin Hcl | 100 | 20 |
| Ozempic | Semaglutide | 100 | 17 |
| Glipizide | Glipizide | 99 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 99 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 91 | 21 |
| Farxiga | Dapagliflozin Propanediol | 89 | 12 |
| Propranolol Hcl | Propranolol Hcl | 89 | suppressed |
| Fenofibrate | Fenofibrate | 86 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 84 | 12 |
| Pregabalin | Pregabalin | 84 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 82 | 47 |
| Tresiba Flextouch U-200 | Insulin Degludec | 82 | 15 |
| Irbesartan | Irbesartan | 80 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 77 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 76 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | suppressed |
| Cephalexin | Cephalexin | 75 | 16 |
| Glimepiride | Glimepiride | 75 | 19 |
| Enalapril Maleate | Enalapril Maleate | 74 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 16 |
| Digoxin | Digoxin | 73 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 72 | 11 |
| Entresto | Sacubitril/Valsartan | 72 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 71 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 35 |
| Primidone | Primidone | 70 | suppressed |
| Metolazone | Metolazone | 68 | suppressed |
| Valsartan | Valsartan | 64 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 61 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 14 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 59 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 58 | suppressed |
| Ramipril | Ramipril | 58 | 13 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 55 | suppressed |
| Carbamazepine | Carbamazepine | 54 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 15 |
| Lovastatin | Lovastatin | 52 | 14 |
| Valproic Acid | Valproic Acid | 52 | suppressed |
| Calcium Acetate | Calcium Acetate | 51 | suppressed |
| Trulicity | Dulaglutide | 51 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 25 |
| Ibuprofen | Ibuprofen | 49 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 48 | suppressed |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Synthroid | Levothyroxine Sodium | 47 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 11 |
| Sucralfate | Sucralfate | 45 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | 12 |
| Glipizide Er | Glipizide | 44 | suppressed |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 12 |
| Novolog | Insulin Aspart | 41 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 40 | suppressed |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Mupirocin | Mupirocin | 39 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Torsemide | Torsemide | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 15 |
| Naproxen | Naproxen | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 33 | 33 |
| Enulose | Lactulose | 33 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | 11 |
| Ondansetron Odt | Ondansetron | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 20 |
| Albuterol Sulfate | Albuterol Sulfate | 31 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Brilinta | Ticagrelor | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 17 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 18 |
| Glyxambi | Empagliflozin/Linagliptin | 24 | suppressed |
| Nabumetone | Nabumetone | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | 11 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Victoza 3-Pak | Liraglutide | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Budesonide | Budesonide | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 13 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Triazolam | Triazolam | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Piroxicam | Piroxicam | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Tresiba | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $577.78 · 29 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, FARXIGA, JARDIANCE, Kerendia, LEQVIO, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VOQUEZNA | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error